Brilinta, 56 pcs., 90 mg, film-coated tablets

Atherosclerotic stenosis or occlusion of the coronary arteries is eliminated in various ways, one of which is stenting of the heart vessels. This technique allows you to expand the lumen of the arterial bed by fixing a stent in it in the form of a cylindrical mesh structure. It is produced on the basis of biocompatible materials (metal, alloys or polymers). By supporting the vascular wall, the stent helps restore the internal diameter of the vessel and its hemodynamics. This is extremely important for restoring coronary blood flow and ensuring complete myocardial trophism.

To avoid thrombus formation and re-stenosis, in addition to the use of structures coated with antithrombotic substances (heparin, nanocarbon, phosphorylcholine, etc.), it is important to use a number of drugs, including Brilinta. Drug therapy at the postoperative stage allows for stable blood thinning and the formation of blood clots in the arterial beds. How much Brilinta to drink after stenting, as well as the features of the postoperative period, will be discussed further.

Compound

Pharmacodynamics

Mechanism of action

Brilinta® contains ticagrelor, a member of the cyclopentyltriazolopyrimidine chemical class, which is a selective and reversible antagonist of the P2Y12 ADP receptor and can prevent ADP-mediated platelet activation and aggregation. Ticagrelor is active when taken orally and interacts reversibly with the platelet P2Y12 ADP receptor. Ticagrelor does not interact with the binding site of ADP itself, but its interaction with the platelet P2Y12 receptor for ADP prevents signal transduction.

Start of action

In patients with stable coronary artery disease, while using acetylsalicylic acid, ticagrelor begins to act quickly, which is confirmed by the results of determining the average value of platelet aggregation inhibition (IAT): 0.5 hours after taking a loading dose of 180 mg of ticagrelor, the average IAT value is approximately 41%, the maximum the IAT value - 89% - is achieved 2-4 hours after taking the drug and is maintained for 2-8 hours. In 90% of patients, the final IAT value - more than 70% - is achieved 2 hours after taking the drug.

End of action

When planning coronary artery bypass grafting (CABG), the risk of bleeding increases if ticagrelor is discontinued less than 96 hours before the procedure.

Data on switching from one drug to another

Switching from clopidogrel to ticagrelor resulted in a 26.4% increase in the absolute value of the IAT, and a change in therapy from ticagrelor to clopidogrel resulted in a decrease in the absolute value of the IAT by 24.5%. It is possible to change therapy from clopidogrel to ticagrelor without interrupting the antithrombotic effect.

Clinical effectiveness

In the PLATO

(
PLATelet Inhibition and Patient Outcomes
) enrolled 18,624 patients who developed symptoms of unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction in the past 24 hours and were treated conservatively or with percutaneous coronary artery disease. intervention (PCI), or CABG (see “Indications”). This study compared ticagrelor 90 mg twice daily with daily acetylsalicylic acid therapy to clopidogrel 75 mg once daily for effectiveness in preventing the composite endpoint of cardiovascular death, myocardial infarction, or stroke through its effect on cardiovascular disease. vascular deaths and myocardial infarction. The loading dose was 300 mg clopidogrel (a dose of 600 mg was also allowed during PCI) or 180 mg ticagrelor.

The effect of ticagrelor appeared early (on the 30th day, an absolute risk reduction (ARR) of 0.6% and a relative risk reduction (RRR) of 12%), with the maintenance of a constant effect of therapy for 12 months, which led to an RRR of 1. 9% and COP by 16% during the year.

Brilinta® reduces the relative risk of the composite endpoint (composite of cardiovascular death, heart attack and stroke) in patients with unstable angina, non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction by 16% (hazard ratio (HR) 0.84 ; 95% confidence interval (CI) 0.77–0.92; p=0.0003), cardiovascular death by 21% (RR 0.79; 95% CI 0.69–0.91; p=0 .0013), myocardial infarction by 16% (RR 0.84; 95% CI 0.75–0.95; p=0.0045).

The effectiveness of Brilinta® is shown in various subgroups of patients, regardless of body weight, gender, history of diabetes mellitus, transient ischemic attack or non-hemorrhagic stroke, revascularization, concomitant therapy (including heparin, glycoprotein IIb/IIIa receptor inhibitors (see “Interactions”) ), final diagnosis (non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and unstable angina) and treatment planned at randomization (invasive or conservative).

Additional analysis suggested a possible relationship with the dose of acetylsalicylic acid, which was expressed in the fact that reduced effectiveness was observed when taking Brilinta® in combination with increased doses of acetylsalicylic acid. The recommended dose of acetylsalicylic acid for continuous use in combination with Brilinta® is 75–150 mg (see “Method of administration and dosage”, “Special instructions”).

Brilinta® demonstrated a statistically significant RR for the composite criterion of death from cardiovascular causes, myocardial infarction and stroke in patients with acute coronary syndrome who were scheduled for invasive intervention (RR 16%, RR 1.7%, p=0.0025) . In an exploratory analysis, Brilinta® also demonstrated an ARR for the primary endpoint in patients with acute coronary syndrome treated with conservative therapy (ARR 15%, ARR 2.3%, nominal p=0.0444). In patients undergoing stenting, ticagrelor showed a reduction in the incidence of stent thrombosis (RR 32%, ARR 0.6%, nominal p=0.0123).

Brilinta® caused a statistically significant RR of 16% (RR 2.1%) for the composite criterion of death from all causes, myocardial infarction and stroke.

The COP of death from all causes while taking Brilinta® was 22% with a nominal significance level of p = 0.0003 and ARR was 1.4%.

Cumulative criterion for combined effectiveness and safety

Pooled outcome measure of combined efficacy and safety (cardiovascular death, myocardial infarction, stroke, or major bleeding as defined by the PLATO

) confirms that within 12 months after an acute coronary syndrome, the beneficial effect of ticagrelor is not counteracted by major bleeding events (RR 8%, ARR 1.4%, OP 0.92; p=0.0257).

What is Brilinta

Brilinta is a modern drug with the active substance ticagrelor, which can interact with adenosine diphosphate blockers. Indicated for adults to prevent atherothrombotic complications. Including patients with a history of a heart attack one year or more ago. The medication reduces the incidence of thrombosis in blood vessels, the risk of repeated heart attacks, ischemic strokes and mortality from cardiovascular diseases by 15-20%. Usually prescribed with small doses of aspirin. Clinical effectiveness has been confirmed by several studies.

The drug is produced in the form of tablets with different dosages. They are easy to swallow with clean water. If the patient has problems swallowing, it is possible to crush the pill to a powder.

Pharmacokinetics

Ticagrelor exhibits linear pharmacokinetics, and the exposure of ticagrelor and the active metabolite ( AR-C124910XX

) is approximately proportional to the dose up to 1260 mg.

Absorption

Ticagrelor is rapidly absorbed with an average Tmax of approximately 1.5 hours. Formation of the main metabolite circulating in the blood AR-C124910XX

(also active) from ticagrelor occurs quickly with an average Tmax of approximately 2.5 hours. After taking ticagrelor on an empty stomach at a dose of 90 mg, Cmax is 529 ng/ml and AUC is 3451 ng·h/ml.

The average absolute bioavailability of ticagrelor is 36%. Ingestion of a high-fat meal does not affect the Cmax of ticagrelor or the AUC of the active metabolite, but leads to a 21% increase in the AUC of ticagrelor and a 22% decrease in the Cmax of the active metabolite. These small changes are of minimal clinical significance; therefore, ticagrelor can be administered without regard to food intake.

Distribution

Vss of ticagrelor is 87.5 l. Ticagrelor and the active metabolite are actively bound to plasma proteins (>99%).

Metabolism

CYP3A4 is the main isoenzyme responsible for the metabolism of ticagrelor and the formation of the active metabolite, and their interactions with other CYP3A substrates range from activation to inhibition. Ticagrelor and its active metabolite are weak inhibitors of P-glycoprotein (P-gp).

The main metabolite of ticagrelor is AR-C124910XX

, which is also active, as confirmed by the results of assessing binding to the platelet P2Y12 ADP receptor
in vitro
. Systemic exposure of the active metabolite is approximately 30–40% of the exposure of ticagrelor.

Excretion

The main route of elimination of ticagrelor is through hepatic metabolism. When isotope-labeled ticagrelor is administered, on average, approximately 57.8% of the radioactivity is excreted in feces and 26.5% in urine. Excretion of ticagrelor and the active metabolite in urine is less than 1% of the dose. The active metabolite is mainly excreted in bile. The average half-life of ticagrelor and the active metabolite was 7 and 8.5 hours, respectively.

Special populations of patients

Elderly patients.

Elderly patients (aged 75 years and older) had higher exposure to ticagrelor (Cmax and AUC approximately 25% higher) and the active metabolite compared to younger patients. These differences are not considered clinically significant (see "Dosage and Administration").

Children.

There are no data on the use of ticagrelor in children.

Floor.

Women had higher exposure to ticagrelor and the active metabolite compared to men. These differences are not considered clinically significant.

Ethnic groups.

The average bioavailability of the drug in Asian patients is 39% higher than in Caucasians. The bioavailability of Brilinta® is 18% lower in black patients compared to Caucasian patients.

Kidney failure.

Exposure to ticagrelor and the active metabolite is approximately 20% lower in patients with severe renal impairment (Cl creatinine <30 ml/min) compared to patients with normal renal function (see "Dosage and Administration").

Liver failure.

Ticagrelor Cmax and AUC were 12% and 23% higher in patients with mild hepatic impairment compared to healthy volunteers. Ticagrelor has not been studied in patients with moderate or severe hepatic impairment and its use in these patients is contraindicated (see Dosage and Administration, Contraindications).

Brilinta™ 90 mg No. 56 tablet p.p.o.

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINE BRILINTA™ Trade name Brilinta™ International nonproprietary name Ticagrelor Dosage form Film-coated tablets, 90 mg COMPOSITION ONE TABLET CONTAINS the active substance - ticagrelor 90 mg, excipients: mannitol, calcium hydrogen phosphate, sodium starch glycolate, hydroxypropylcellulose, magnesium stearate, shell composition: hypromellose 2910, titanium dioxide (E171), talc, macrogol 400, yellow iron oxide (E172). Description Round, biconvex, yellow film-coated tablets, engraved with “” on one side and smooth on the other. Pharmacotherapeutic group Anticoagulants. Platelet aggregation inhibitors. ATC code B01AC24 Pharmacological properties Pharmacokinetics Absorption Ticagrelor is rapidly absorbed with an average tmax of approximately 1.5 hours. The formation of the main circulating metabolite AR‑C124910XX (also active) from ticagrelor occurs quickly with an average tmax of approximately 2.5 hours. Cmax and AUC of ticagrelor and the active metabolite increase proportionally to the dose over the dose range studied (30 – 1260 mg). The mean absolute bioavailability of ticagrelor is 36% (range, 25.4% to 64.0%). Ingestion of a high-fat meal did not affect the Cmax of ticagrelor or the AUC of the active metabolite, but resulted in a 21% increase in the AUC of ticagrelor and a 22% decrease in the Cmax of the active metabolite. These small changes are of minimal clinical significance; therefore, ticagrelor can be administered without regard to food intake. Distribution The volume of distribution of ticagrelor at steady state is 87.5 L. Ticagrelor and the active metabolite are widely bound to plasma proteins (> 99.7%). Metabolism by CYP3A4 is the main isoenzyme, the main metabolite of ticagrelor is AR-C124910XX, which is also active, as confirmed by the results of assessing binding to the platelet P2Y12 ADP receptor in vitro. Systemic exposure of the active metabolite is approximately 30-40% of the exposure of ticagrelor. Excretion The main route of elimination of ticagrelor is through hepatic metabolism. The active metabolite is mainly excreted in bile. The mean half-lives of ticagrelor and the active metabolite were 6.9 hours (range, 4.5–12.8 hours) and 8.6 hours (range, 6.5–12.8 hours), respectively. Special Populations Elderly Patients Elderly patients (aged 75 years and older) had higher exposure to ticagrelor and the active metabolite (Cmax and AUC by approximately 25%) compared to younger patients. These differences are not considered clinically significant. Children There are no data on the use of ticagrelor in children. Gender Women had higher exposure to ticagrelor and the active metabolite compared to men. These differences are not considered clinically significant. Ethnic groups The average bioavailability of the drug in Asian patients is 39% higher than in Caucasians. The bioavailability of Brilinta is 18% lower in patients of the Negroid race compared to patients of the Caucasian race. In pharmacological studies, exposure (Cmax and AUC) to Brilinta in Japanese subjects was approximately 40% (20% after adjustment for body weight) higher than in Caucasians. Renal impairment Exposure to ticagrelor and its active metabolite is approximately 20% lower in patients with severe renal impairment (creatinine clearance <30 ml/min) compared to patients with normal renal function. Ticagrelor inhibition of platelet aggregation was similar in the two groups, but response to therapy varied more in patients with severe renal impairment. There is no need to adjust the dose of the drug in patients with renal failure. There is no information on the use of the drug in patients on hemodialysis. Hepatic impairment Cmax and AUC of ticagrelor were 12% and 23% higher in patients with mild hepatic impairment compared with healthy volunteers, respectively, but ticagrelor inhibition of platelet aggregation was similar in the two groups. There is no need to adjust the dose of the drug in patients with mild hepatic impairment. Ticagrelor has not been studied in patients with moderate or severe hepatic impairment. Pharmacodynamics Onset of action In patients with stable coronary artery disease on the background of the use of acetylsalicylic acid, Brilinta™ begins to act quickly, which is confirmed by the results of determining the average value of platelet aggregation inhibition (IAT): 0.5 hours after taking the loading dose - 180 mg Brilinta™ average value IAT is approximately 41%, the maximum IAT value of 87.9% - 89.6% is achieved 2-4 hours after taking the drug. In 90% of patients, the final IAT value of more than 70% is achieved 2 hours after taking the drug. High inhibition of platelet aggregation (87%-89%) by Brilinta™ is maintained for 2-8 hours. End of action Once the concentrations of Brilinta™ and its active metabolite have decreased below the level required to saturate the receptors, the IAT gradually decreases with decreasing plasma concentrations. Since Brilinta™ binding is reversible, restoration of platelet function is independent of regeneration of the platelet pool. The effect of Brilinta™ on IAT ceases faster than that of clopidogrel, which is confirmed by the magnitude of the decline in effect within 4-72 hours after taking the last dose of the drug (see section "Special Instructions"). The mean final IAT value measured after the last dose of ticagrelor is approximately 20-30% higher than that of clopidogrel. However, 24 hours after the last dose of Brilinta™, the percentage of platelet aggregation inhibition (%IAT) is the same as that of clopidogrel, and from 72 hours to 7 days after taking Brilinta™, the %IAT is lower than that of clopidogrel. The mean %IAT 72 hours (Day 3) after Brilinta™ was comparable to the mean %IAT 5 days after clopidogrel, and the %IAT 5 days after Brilinta™ was similar to the %IAT 7 days after clopidogrel. which is not statistically different from placebo. Switching data Switching from clopidogrel to Brilinta™ resulted in a 26.4% increase in absolute IAT value, and switching from Brilinta™ to clopidogrel resulted in a 24.5% decrease in absolute IAT value. It is possible to change therapy from clopidogrel to Brilinta™ without interrupting the antithrombotic effect. Pooled Pooled Efficacy and Safety Pooled Pooled Efficacy and Safety (cardiovascular death, myocardial infarction, stroke, or "overall major bleeding" as defined by the PLATO trial) supports the benefit of Brilinta™ (RRR 8%, ARR 1, 4%, OP 0.92; p=0.0257) within 12 months after the development of symptoms of acute coronary syndrome. Indications for use: prevention of atherothrombotic complications in adult patients with acute coronary syndrome (unstable angina, non-ST segment elevation myocardial infarction [NSTEMI] or ST-segment elevation myocardial infarction [STEMI]), in combination with acetylsalicylic acid (ASA), including patients receiving drug therapy, and patients who underwent percutaneous coronary angioplasty (PCA) or coronary artery bypass grafting (CABG) Method of administration and dosage For oral administration. Brilinta™ can be taken regardless of food intake. Brilinta™ should be started with a single loading dose of 180 mg (two 90 mg tablets) and then continued at 90 mg twice daily. Patients taking Brilinta™ should take acetylsalicylic acid daily (from 75 mg to 150 mg with continuous use), unless there are specific contraindications. Interruptions in therapy should be avoided. A patient who misses a dose of Brilinta™ should take only one 90 mg tablet (next dose) at the scheduled time. Clinicians who wish to switch a patient from clopidogrel therapy to Brilinta™ should administer the first dose of Brilinta™ 90 mg 24 hours after the last dose of clopidogrel. It is recommended to continue therapy with Brilinta™ for at least 12 months, unless there is a clinical need for early discontinuation of the drug. In patients with acute coronary syndrome, early discontinuation of any antithrombotic therapy, including Brilinta™, may increase the risk of death due to cardiovascular disease or myocardial infarction as a result of the underlying disease. Elderly patients No dose adjustment required. Patients with renal insufficiency No dosage adjustment is required in patients with renal insufficiency. There is no information on the use of Brilinta™ in patients on hemodialysis. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Brilinta™ has not been studied in patients with moderate or severe hepatic impairment. Side effects Adverse reactions are classified by frequency of development and organ system. Frequency categories are determined according to the following conventions: very often (≥ 1/10), often (≥ 1/100 to <1/10), not often (≥1/1000 to <1/100), rarely (≥1 /10000 to <1/1000), very rare (<1/10000), unknown (based on known data, cannot be estimated). Common (≥ 1/100 to <1/10) - dyspnea - epistaxis - gastrointestinal bleeding - skin bleeding - hematoma - bleeding at the procedure site Uncommon (≥1/1000 to <1/100) - intracranial hemorrhage - dizziness, headache - eye hemorrhages (intraocular, conjunctival, retinal) - hemoptysis - hematemesis - bleeding from gastrointestinal ulcers - hemorrhoidal bleeding - gastritis - oral bleeding (including bleeding gums) - vomiting, diarrhea, nausea, abdominal pain, dyspepsia - rash, itching - bleeding from the urinary tract - vaginal bleeding (including metrorrhagia) - postoperative bleeding Rarely (≥1/10000 to <1/1000) - hyperuricemia - confusion - paresthesia - ear bleeding - retroperitoneal bleeding - constipation - hemarthrosis - increased creatinine in the blood - bleeding from the wound surface, post-traumatic bleeding Contraindications - hypersensitivity to the active substance or to any excipient - presence of pathological bleeding - history of intracranial hemorrhage - moderate or severe liver failure - combined use of ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir), as coadministration may result in a significant increase in ticagrelor exposure - pregnancy and lactation Drug Interactions Brilint™ is primarily a CYP3A4 substrate and a weak CYP3A4 inhibitor. Brilinta™ is also a P-gp substrate and a weak P-gp inhibitor and may increase exposure to P-gp substrates. Effect of other medicinal products on Brilinta Drugs metabolized by CYP3A4 CYP3A4 inhibitors - Potent CYP3A4 inhibitors - co-administration of ketoconazole with Brilinta™ results in an increase in the Cmax and area under the curve (AUC) of Brilinta™ by 2.4 times and 7.3 times, respectively. Cmax and area under the curve (AUC) of the active metabolite decreased by 89% and 56%, respectively. It can be assumed that other strong CYP3A4 inhibitors (clarithromycin, nefazodone, ritonavir and atazanavir) have similar effects and their combined use with Brilinta™ is contraindicated. - Moderate inhibitors of CYP3A4 - combined use of diltiazem with Brilinta™ leads to an increase in Cmax of ticagrelor by 69%, and the area under the curve (AUC) by 2.7 times, and a decrease in Cmax of the active metabolite by 38% without changing the area under the curve (AUC) . Brilinta™ does not affect plasma levels of diltiazem. Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole) can be expected to have similar effects and may be co-administered with Brilinta™ to the same extent. CYP3A inducers Co-administration of rifampicin with Brilinta™ results in a decrease in Cmax and area under the curve (AUC) of Brilinta™ by 73% and 86%, respectively. The Cmax of the active metabolite remained unchanged, and the area under the curve (AUC) decreased by 46%, respectively. It can be expected that other CYP3A inducers (eg, dexamethasone, phenytoin, carbamazepine and phenobarbital) will also reduce the effects of Brilinta™. Concomitant use of Brilinta™ with strong CYP3A inducers may reduce the exposure and effectiveness of Brilinta™. Other Clinical pharmacological interaction studies indicate that coadministration of Brilinta™ with gaperin, enoxaparin and acetylsalicylic acid or desmopressin does not have any effect on the pharmacokinetics of Brilinta™ or its active metabolite, or on ADP-induced platelet aggregation compared with administration of Brilinta™ alone. . If clinically indicated, drugs that alter hemostasis should be used with caution in combination with Brilinta™. There are no data on the combined use of Brilinta™ with potent P-glycoprotein inhibitors (for example, verapamil, quinidine, cyclosporine), which may increase the exposure of Brilinta™. If clinically indicated, their combined use requires caution. Effect of Brilinta™ on other medicinal products Drugs metabolized by CYP3A4 Simvastatin - co-administration of ticagrelor with simvastatin results in an 81% increase in simvastatin Cmax and a 56% increase in area under the curve (AUC) and a 64% increase in simvastatin acid Cmax. , and the area under the curve (AUC) - by 52%, in some individual cases with an increase of 2 - 3 times. Concomitant use of Brilinta™ and simvastatin at doses greater than 40 mg per day may result in side effects from simvastatin and should therefore be weighed against the potential benefit before use. Simvastatin does not affect Brilinta™ plasma levels. Brilinta™ may have similar effects to lovastatin. Concomitant use of Brilinta™ with simvastatin or lovastatin at a dose of more than 40 mg is not recommended. Atorvastatin – co-administration of atorvastatin and Brilinta™ results in an increase in atorvastatin acid Cmax by 23% and area under the curve (AUC) by 36%. A similar increase in area under the curve (AUC) and Cmax was observed for all atorvastatin acid metabolites. These increases are not considered clinically significant. Brilinta™ is a weak inhibitor of CYP3A4. Co-administration of Brilinta™ with CYP3A4 substrates with a narrow therapeutic index (eg, cisapride or ergot alkaloids) is not recommended as Brilinta™ may increase the exposure of these drugs. Drugs Metabolized by CYP2C9 Co-administration of Brilinta™ with tolbutamide did not alter the plasma levels of either drug, suggesting that Brilinta™ is not a CYP2C9 inhibitor and is unlikely to affect the CYP2C9 mediated metabolism of drugs such as warfarin and tolbutamide. Oral contraceptives: Concomitant use of Brilinta™ with levonorgestrel and ethinyl estradiol increases the exposure of ethinyl estradiol by approximately 20%, but does not affect the pharmacokinetics of levonorgestrel. When levonorgestrel and ethinyl estradiol are taken concomitantly with Brilinta™, no clinically significant effect on the effectiveness of oral contraceptives is expected. P-glycoprotein (P-gp) substrates (including digoxin, cyclosporine) Co-administration with Brilinta™ results in an increase in digoxin Cmax by 75% and area under the curve (AUC) by 28%. Average digoxin trough levels increased by approximately 30% when coadministered with Brilinta™, with the maximum increased by up to 2-fold in some isolated cases. In the presence of digoxin, there was no effect on the Cmax and area under the curve (AUC) of Brilinta™ and its active metabolite. Therefore, when Brilinta™ is co-administered with P-gp-dependent drugs with a narrow therapeutic index, such as digoxin or cyclosporine, appropriate clinical and/or laboratory monitoring is recommended. Other Concomitant Treatment Options Drugs Known to Cause Bradycardia Due to observations of primarily asymptomatic episodes of ventricular asystole and bradycardia, caution should be exercised when coadministering Brilinta™ with drugs known to cause bradycardia. The joint use of the Brilin ™ drug with heparin, enoxaparin or desmopressin did not affect the indicators of activated partial thromboplastin time (APTT), activated coagulation time (ACT) or factor XA. However, due to potential pharmacodynamic interactions, caution should be observed with the joint use of the drug Brilin ™ with drugs, which, as you know, change hemostasis. Due to the messages about the pathological hemorrhages of the skin when taking selective serotonin requament (SSRIS) (for example, parksetin, sertralin and citralopram), care should be taken when taking selective serotonin (SSRIS) rejection (SSRIS) with the drug Brilin ™, as this is may lead to an increase in the risk of bleeding. Special instructions The risk of bleeding, as with other antitrombotic drugs, when prescribing the drug Brilin ™, it is necessary to assess the ratio of the benefits of preventing thrombotic events and risk in patients with increased risk of bleeding. It is necessary to take into account the following:-the predisposition of patients to the development of bleeding (for example, due to the recently received injury, recently carried out by the operation, active or recent gastrointestinal bleeding or intracranial hemorrhage, or severe liver failure). - the concomitant use of drugs that can increase the risk of bleeding (for example, non -steroidal anti -inflammatory drugs, oral anticoagulants and/or fibrinolytics, taken within 24 hours before taking Brilintus ™). There is no data on the use of the drug Brilin ™ and hemostatic efficiency of transfusions by platelets; Brilin ™ can inhibit transfused blood platelets. Since with the accompanying use of the drug Brilin ™ and Desmopressin, the standardized bleeding time did not decrease, it is unlikely that desmopressin will effectively stop bleeding. Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor VIIa may enhance hemostasis. After establishing the cause of bleeding and its relief, you can resume therapy with the drug Brilin ™. Surgical surgery If the patient needs surgical intervention, then doctors should take into account the clinical profile of each patient, as well as evaluate the ratio of the benefit-risk from continuing antitrombotic therapy when determining the time of termination of the use of the drug Brilin ™. If the patient is subjected to a planned operation and an antitrombotic effect is not desirable, then the therapy with Brilin ™ should be stopped 5 days before surgery. Patients with the risk of bradycardia development in connection with the detection in the previously conducted clinical study, mainly asymptomatic ventricular asystoli, patients with an increased risk of bradycardia (for example, patients without a pacemaker who have a sinus unit syndrome, atrioventricular blockade of the 2nd or 3rd -a degree; a fainting associated with bradycardia) was not included in the basic study to assess the safety and effectiveness of the drug Brilin. Therefore, in connection with limited clinical experience in the use of the drug in these patients, it is recommended to prescribe the drug Brilin to such patients with caution. Shortness of breath of shortness of breath, noted with the use of the drug Brilin ™, is usually weak or moderate in its intensity, often passes as the treatment continues with the drug. If the patient has developed a new episode of shortness of breath, shortness of breath is preserved or worsened during the use of Brilin ™, then other causes of shortness of breath, such as the presence of the underlying disease that may require treatment. If it is established that shortness of breath is caused by therapy with the drug Brilin ™, taking the drug Brilin ™ should be stopped. Increase creatinine during treatment with Brilintin ™, creatinine levels may increase. The mechanism was not clarified. The renal function should be checked after one month, and subsequently according to routine medical practice, paying special attention to patients ≥ 75 years old, patients with medium/severe renal failure and those who received concomitant treatment with angiotensin-II receptors (ARB). An increase in uric acid should observe precautions when taking Brilinth ™ patients who have a history of hyperuricemia or gouty arthritis. As a precaution, the use of BRILLINTA ™ in patients with uHC with nephropathy is not recommended. Others should avoid the joint use of the Brilin ™ drug with powerful CYP3A4 inhibitors (for example, ketoconazole, clarithromycin, nephazadon, ritonavir and atazanavir), as joint use can lead to a significant increase in the effects of the Brilin ™ drug. The joint use of Brindy ™ with powerful CYP3A4 inducers (for example, rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital) should be avoided, so joint use can lead to a significant decrease in the effects and efficiency of Brilinths ™. The joint use of the Brilin ™ and CYP3A4 substrates with a narrow therapeutic range (for example, CIZAPAPAPADID and CLOSELS) is not recommended, since BRILINT ™ can increase the effects of these drugs. The joint use of Brilin ™ with Simvastatin or Lovastatin at a dose of more than 40 mg is not recommended. With the joint use of digoxin and the drug Brilin ™, careful clinical and laboratory monitoring is recommended. There is no data on the joint use of the Brilin ™ drug with powerful P-glycoprotein inhibitors (P-GP) (for example, verapamil, quinidine, cyclosporin), which can increase the effects of BDI ™. If it is impossible to avoid joint use, then when using it, it is necessary to observe precautions of the cessation of therapy if necessary to stop the use of the Brilin ™ drug, the risk of developing cardiovascular events increases. Premature termination of therapy should be avoided. If it is necessary to temporarily stop the therapy with the drug Brilin ™ in connection with the development of an undesirable phenomenon, you should resume therapy as soon as possible if the benefits of the drug outweigh the risks from the development of an undesirable phenomenon, or if an undesirable phenomenon was resolved. Children safety and effectiveness of the drug Brilin ™ in children under the age of 18 have not been established. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms of Brilin ™ do not affect the ability to drive transport and mechanisms, however, in the treatment of acute coronary syndrome, dizziness and confusion were observed. Therefore, patients with such symptoms should be carried out with caution for vehicles or work with mechanisms. Overdose symptoms: bleeding is an alleged pharmacological effect of an overdose of the drug Brilin ™, therefore, with the development of bleeding, it is necessary to carry out appropriate supporting measures. Other clinically significant adverse reactions that can be found during an overdose include dispensom and ventricular asystole episodes. Treatment: specific antidote does not exist; In case of an overdose, treatment should be symptomatic. Brilin ™ is not excreted in hemodialysis. General supportive therapy, monitoring the patient and control of the function of vital organs and systems (ECG-monitoring) are recommended. The form of release and packaging of 14 tablets in a blister pack of polyvinyl chloride, polyvinylidichloride and foil aluminum printed lacquered. In 4 blisters, along with instructions for medical use in the state and Russian languages, they are invested in a pack of cardboard. Storage conditions Store at a temperature not exceeding 30°C. Keep out of the reach of children! Shelf life 3 years Do not use after the expiration date indicated on the package. Conditions of the vacation from pharmacies according to the recipe manufacturer AB AB, S-151 85 Contributions, Sweden Packer Astrazeneck AB, Sweden owner of the registration certificate of Astrazeneck Yuk Limited, UK address of the organization that accepts the claims on the territory of the Republic of Kazakhstan from consumers on the quality of products (goods) representation of ZAK Astrazenka Yu-Kay Limited »Phone, fax e-mail Brillin-trademark, property of the Astrazenka group of companies.

Contraindications

hypersensitivity to ticagrelor or any of the components of the drug;

active pathological bleeding;

history of intracranial hemorrhage;

moderate or severe liver failure;

co-administration of ticagrelor with strong CYP3A4 inhibitors (for example, ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir);

children under 18 years of age (due to the lack of data on the effectiveness and safety of use in this group of patients).

Carefully:

patients are predisposed to the development of bleeding (for example, due to recent trauma, recent surgery, bleeding disorders, active or recent gastrointestinal bleeding) (see "Special Instructions"); patients with concomitant therapy with drugs that increase the risk of bleeding (i.e. NSAIDs, oral anticoagulants and/or fibrinolytics) within 24 hours before taking Brilinta®; patients with an increased risk of developing bradycardia (for example, patients with sick sinus syndrome without a pacemaker, with second or third degree AV block, syncope associated with bradycardia) due to insufficient experience with the clinical use of Brilinta® (see “Special Instructions”); combined use with drugs that cause bradycardia; patients with bronchial asthma and COPD (if the patient reports a new episode of shortness of breath, prolonged shortness of breath or worsening shortness of breath, an examination should be carried out, and in case of intolerance, treatment with ticagrelor should be discontinued); while taking Brilinta®, creatinine levels may increase (see “Side effects”, “Special instructions”), and therefore it is necessary to assess renal function in accordance with routine clinical practice, paying special attention to patients 75 years of age and older , patients with moderate or severe renal failure, patients receiving therapy with angiotensin receptor antagonists; patients with a history of hyperuricemia or gouty arthritis.

As a preventive measure, the use of ticagrelor should be avoided in patients with hyperuricemic nephropathy.

The combined use of ticagrelor and a high maintenance dose of acetylsalicylic acid (more than 300 mg) is not recommended.

When using digoxin and Brilinta® together, careful clinical and laboratory monitoring (heart rate and, if clinically indicated, also ECG and digoxin concentration in the blood) is recommended.

There is no data on the combined use of ticagrelor with potent P-gp inhibitors (for example, verapamil, quinidine and cyclosporine), and therefore their combined use should be carried out with caution (see “Interactions”).

How much should you take Brilinta after stenting?

Only an experienced specialist can conduct regular monitoring of the patient’s condition, and, if necessary, take timely measures to eliminate bleeding. This is especially important for patients with coronary heart disease, who often experience bleeding during treatment with this medicine.

Only a doctor, taking into account the specific clinical picture, determines how much Brilinta to drink. According to the manufacturer's instructions, this medication must be taken for at least a year. After this period, the possibility of excluding the antithrombotic from drug therapy is considered, taking into account laboratory tests.

Use during pregnancy and breastfeeding

There are no or limited data on the use of Brilinta® in pregnant women.

In animal studies, ticagrelor caused a slight decrease in maternal weight gain, a decrease in the viability of the newborn and its body weight, and growth retardation. Brilinta® is not recommended during pregnancy.

Available pharmacodynamic and toxicological data in animals have shown that ticagrelor and its active metabolites are excreted in milk. A risk to the newborn/infant cannot be excluded. It is not recommended to use Brilinta® while breastfeeding.

Side effects

According to the PLATO

, the most common adverse events reported in patients taking ticagrelor were shortness of breath, bruises and nosebleeds.

Adverse reactions are classified by frequency and organ system class. The frequency of adverse reactions is determined using the following symbols: very often (≥1/10); often (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10000, <1/1000).

Table

Adverse drug reactions by incidence and organ system class ( SOC

)

a

Hyperuricemia, increased concentration of uric acid in the blood;
see Laboratory Abnormalities
below.

b

Cerebral hemorrhage, intracranial hemorrhage, hemorrhagic stroke.

c

Dyspnea, dyspnea on exertion, dyspnea at rest, dyspnea at night.

d

Gastrointestinal bleeding, rectal bleeding, intestinal bleeding, melena, positive occult blood test.

e

Bleeding from a gastrointestinal ulcer, bleeding from a gastric ulcer, bleeding from a duodenal ulcer, bleeding from a peptic ulcer.

f

Subcutaneous hematoma, cutaneous and subcutaneous hemorrhages, petechiae.

g

Contusion, hematoma, ecchymosis, increased tendency to bruise, traumatic hematoma.

h

Hematuria, bleeding from the urinary tract.

i

Bleeding from the site of vascular puncture, hematoma at the site of vascular puncture, bleeding from the injection site, bleeding from the puncture site, bleeding from the catheterization site.

Description of some adverse reactions

Bleeding

In the PLATO

The following definitions of bleeding were used:

— Major lethal/life-threatening bleeding:

fatal or intracranial hemorrhage, or bleeding into the pericardial cavity with cardiac tamponade, or hypovolemic shock, or severe hypotension caused by bleeding and requiring the use of vasoconstrictors or surgery, or clinically obvious bleeding accompanied by a decrease in hemoglobin level by more than 50 g/l or requiring transfusion of 4 or more units of whole blood or red blood cells;

— major other bleeding:

causing significant disability of the patient (for example, intraocular hemorrhage with irreversible loss of vision) or clinically obvious bleeding, accompanied by a decrease in hemoglobin levels by 30-50 g/l or requiring transfusion of 2-3 units of whole blood or red blood cells;

— minor bleeding:

requires medical intervention to stop or treat bleeding (eg, nosebleeds requiring a hospital visit for nasal packing).

Brilinta® and clopidogrel did not differ in the incidence of major bleeding overall according to PLATO

(11.6%/year and 11.2%/year, respectively), fatal/life-threatening bleeding according to
PLATO
(5.8%/year in both groups).
However, the incidence of combined major and minor bleeding according to PLATO
was higher in the ticagrelor group (16.1%) compared with clopidogrel (14.6%, p = 0.0084).

Age, sex, weight, race, geographic region, comorbidities, concomitant medications, and medical history, including prior stroke and transient ischemic attack, did not affect the incidence of overall and nonprocedure-related major bleeding according to PLATO

. No groups were identified with an increased risk of bleeding.

Bleeding associated with CABG.

PLATO
study, 42% of 1584 patients (12% of the cohort) undergoing CABG experienced major fatal/life-threatening bleeding, with no significant differences in both treatment groups. Fatal bleeding associated with CABG surgery occurred in 6 patients in each treatment group.

Non-CABG-related bleeding and non-procedure-related bleeding.

Brilinta® and clopidogrel did not differ in the incidence of major fatal/life-threatening bleeding not related to CABG according to
PLATO
, but Brilinta® was more likely to develop major bleeding overall according to the
PLATO
(4.5%/year compared with 3.8%/year; p=0.0264). When removing cases of CABG-related bleeding, there were more bleeding events in the ticagrelor group (3.1%/year) than in the clopidogrel group (2.3%/year; p=0.0058). Discontinuation due to non-procedure-related bleeding was more common with ticagrelor (2.9%) compared with clopidogrel (1.2%, p<0.001).

Intracranial hemorrhage.

There were more non-procedure-related intracranial hemorrhages in the ticagrelor group (n=27 bleedings in 26 patients, 0.3%) than in the clopidogrel group (n=14 bleedings, 0.2%), of which 11 bleedings were associated with ticagrelor. and 1 on clopidogrel were fatal. However, there was no significant difference in the total number of fatal bleeding events.

Dyspnea

Adverse events in the form of dyspnea (shortness of breath, dyspnea at rest, dyspnea on exercise, paroxysmal nocturnal dyspnea and nocturnal dyspnea) in combination developed in 13.8% of patients receiving Brilinta® and in 7.8% of patients taking clopidogrel. The researchers found that 2.2% of patients in the ticagrelor group had treatment-related shortness of breath. Most cases of shortness of breath were mild or moderate in intensity and occurred as single episodes immediately after initiation of therapy.

Approximately 30% of all cases of shortness of breath resolved within 7 days. Dyspnea developed more often in older patients, in patients with congestive heart failure, COPD or bronchial asthma at the beginning of the study. Brilinta® was discontinued in 0.9% of patients due to shortness of breath. Dyspnea was not associated with the development of new or worsening of existing heart or lung disease (see "Special Instructions").

Brilinta® does not affect respiratory function parameters.

Deviations in laboratory values

Serum creatinine concentrations increased by more than 30% in 25.5% of patients and by more than 50% in 8.3% of patients receiving Brilinta®. An increase in creatinine of more than 50% was more common in patients over 75 years of age, patients with severe renal impairment at study entry, and patients receiving angiotensin receptor antagonist therapy. The overall incidence of renal adverse events was 4.9% in patients on ticagrelor, but investigators attributed them to the drug in 0.6% of cases.

Serum uric acid concentrations increased above the ULN in 22% of patients receiving Brilinta®. Adverse events associated with hyperuricemia were observed in 0.5% of cases with ticagrelor, of which the researchers associated 0.05% of cases with ticagrelor. Gouty arthritis occurred in 0.2% of patients treated with ticagrelor, none of which were considered drug-related by the investigator.

Drug interactions

Impact of other medicinal products on Brilinta®

Drugs metabolized by the CYP3A4 isoenzyme

CYP3A4 inhibitors

Potent CYP3A4 inhibitors: Coadministration of ketoconazole with ticagrelor increases the Cmax and AUC of ticagrelor by 2.4 and 7.3 times, respectively. Cmax and AUC of the active metabolite are reduced by 89 and 56%, respectively. Other strong CYP3A4 inhibitors (clarithromycin, nefazodone, ritonavir and atazanavir) will have the same effects, so their combined use with Brilinta® is contraindicated (see “Contraindications”, “Special Instructions”).

Moderate inhibitors of CYP3A4: co-administration of diltiazem with ticagrelor increases the Cmax of ticagrelor by 69% and the AUC by 2.7 times and reduces the Cmax of the active metabolite by 38%, and the AUC does not change. Ticagrelor does not affect plasma concentrations of diltiazem. Other moderate CYP3A4 inhibitors (eg amprenavir, aprepitant, erythromycin, fluconazole) can be co-administered with Brilinta.

CYP3A4 inducers

Co-administration of rifampicin with ticagrelor reduced the Cmax and AUC of ticagrelor by 73 and 86%, respectively. The Cmax of the active metabolite does not change, and the AUC decreases by 46%. Other CYP3A4 inducers (eg dexamethasone, phenytoin, carbamazepine and phenobarbital) are likely to reduce the exposure of Brilinta. Potent inducers of CYP3A4 may reduce the exposure and effectiveness of Brilint®.

Other

According to the results of pharmacological interaction studies, the concomitant use of ticagrelor with heparin, enoxaparin and acetylsalicylic acid or desmopressin does not affect the pharmacokinetics of ticagrelor, its active metabolite and ADP-dependent platelet aggregation. If there are clinical indications for prescribing drugs that affect hemostasis, they should be used with caution in combination with Brilinta® (see “Contraindications”, With caution

).

There are no data on the combined use of Brilinta® with potent P-gp inhibitors (for example, verapamil, quinidine and cyclosporine), which may increase the exposure of ticagrelor. If their combined use cannot be avoided, it should be used with caution (see “Contraindications”, With caution

, "Special instructions").

Effect of Brilinta® on other drugs

Drugs metabolized by the CYP3A4 isoenzyme

Simvastatin: Concomitant use of ticagrelor and simvastatin increases the Cmax and AUC of simvastatin by 81 and 56%, respectively, and increases the Cmax and AUC of simvastatin acid by 64 and 52%, respectively, with some cases increasing these values ​​by 2-3 times. Concomitant use of simvastatin at a dose above 40 mg/day with ticagrelor may lead to the development of side effects of simvastatin, and the potential risk-benefit ratio must be assessed. The combined use of Brilinta® with simvastatin and lovastatin at a dose exceeding 40 mg is not recommended.

Atorvastatin: Concomitant use of atorvastatin and ticagrelor increases the Cmax and AUC of atorvastatin acid metabolites by 23 and 36%, respectively. A similar increase in Cmax and AUC values ​​is observed for all metabolites of atorvastatin acid. These changes were considered clinically insignificant.

Similar effects to statins metabolized by CYP3A4 cannot be excluded. In the PLATO

Patients receiving ticagrelor took various statins, with no safety concerns reported in 93% of patients taking this group of drugs.

Ticagrelor is a moderate CYP3A4 inhibitor. Concomitant use of Brilint® with CYP3A4 substrates with a narrow therapeutic index (for example, cisapride or ergot alkaloids) is not recommended, because Ticagrelor may increase the exposure of these drugs.

Drugs metabolized by the CYP2C9 isoenzyme

Concomitant use of ticagrelor and tolbutamide did not change plasma concentrations of either drug, indicating that ticagrelor is not a CYP2C9 inhibitor and is unlikely to affect the CYP2C9-mediated metabolism of drugs like warfarin and tolbutamide.

Oral contraceptives

Coadministration of ticagrelor, levonorgestrel and ethinyl estradiol increases the exposure of ethinyl estradiol by approximately 20% but does not affect the pharmacokinetics of levonorgestrel. No clinically significant effect on the effectiveness of contraception is expected with the simultaneous use of levonorgestrel, ethinyl estradiol and Brilinta®.

P-gp substrates (including digoxin and cyclosporine)

Concomitant use of digoxin with ticagrelor increases the Cmax and AUC of digoxin by 75 and 28%, respectively. When taken together with ticagrelor, on average, the lowest level of digoxin increased by 30%, in some individual cases by two times. Cmax and AUC of ticagrelor did not change with digoxin. Therefore, it is recommended to carry out appropriate clinical and/or laboratory monitoring during simultaneous use of Brilinta® and P-gp-dependent drugs with a narrow therapeutic index, such as digoxin and cyclosporine.

Other concomitant therapy

When using Brilinta® together with drugs that can cause bradycardia, caution should be exercised. However, in the PLATO

no clinically significant adverse events were observed when used concomitantly with one or more drugs that can cause bradycardia (for example, 96% - beta-blockers, 33% - calcium channel blockers, including diltiazem and verapamil, and 4% - digoxin).

In the PLATO

Brilinta® was predominantly prescribed in combination with acetylsalicylic acid, proton pump inhibitors, statins, β-blockers, ACE inhibitors and angiotensin receptor antagonists as part of long-term administration, as well as with heparin, low molecular weight heparins, glycoprotein IIb/IIIa receptor inhibitors for intravenous administration. within short-term therapy. The results of these studies did not reveal clinically significant adverse interactions.

Co-administration of Brilinta® with heparin, enoxaparin or desmopressin had no effect on aPTT, activated clotting time and factor Xa test, however, due to potential pharmacodynamic interactions, caution is required when combined with drugs that affect hemostasis.

Due to reports of subcutaneous hemorrhage with selective serotonin reuptake inhibitors (eg paroxetine, sertraline and citalopram), caution is recommended when co-administering them with Brilinta.

Directions for use and doses

Inside.

Brilinta® can be taken with or without food.

The use of Brilinta® should be started with a single loading dose of 180 mg (2 tablets of 90 mg each) and then continued at 90 mg 2 times a day.

Patients taking Brilinta® should take acetylsalicylic acid from 75 to 150 mg daily with continuous use (see “Pharmacodynamics”), unless there are specific contraindications.

Interruptions in therapy should be avoided. A patient who has missed a dose of Brilinta® should take only 1 tablet. 90 mg (next dose) at scheduled time.

If necessary, patients taking clopidogrel can be switched to taking Brilinta® (see “Pharmacodynamics”).

It is recommended to carry out therapy with Brilinta® for 12 months, except in cases of clinical need for early discontinuation of the drug (see “Pharmacodynamics”). Data on the use of ticagrelor for more than 12 months are limited. In patients with acute coronary syndrome, early discontinuation of any antiplatelet therapy, including Brilinta®, may increase the risk of cardiovascular death or myocardial infarction as a result of the underlying disease (see "Special Instructions"). Premature discontinuation of the drug should be avoided.

Elderly patients.

No dose adjustment is required (see “Pharmacokinetics”).

Patients with renal failure.

There is no need to adjust the dose of the drug in patients with renal failure (see “Pharmacokinetics”). There is no information on the use of Brilinta® in patients on hemodialysis, therefore its use in these patients is not indicated.

Patients with liver failure.

There is no need to adjust the dose of the drug in patients with mild hepatic impairment. Brilinta® has not been studied in patients with moderate or severe hepatic impairment, therefore its use in these patients is contraindicated (see “Pharmacokinetics”, “Contraindications”).

Children.

The safety and effectiveness of Brilinta® in children under 18 years of age for its approved indication in adults has not been established.

Brilinta for heart attack prevention

Brilinta is used not only for stenting, but also against the background of problems with blood supply to the heart and the threat of myocardial infarction. Or as an adjunct to drug therapy after balloon angioplasty.

The drug is rational to use, since a sudden obstruction to the normal flow of blood in the branches of the coronary artery is the direct cause of a heart attack. Blood clots are to blame in 95–97% of cases.

A loading dose of Brilinta is not prescribed to patients in the case of heart attack prevention. Typically the daily dose is 120 mg/day, divided into 2 doses. If the patient has previously taken other medications, a daily break is necessary. The exact treatment regimen and dosage is determined by the attending physician.

Overdose

Ticagrelor is well tolerated in a single dose of up to 900 mg.

Symptoms:

in the only dose-escalation study, GI adverse effects were dose-limiting. Other clinically significant adverse events that could occur with overdose were shortness of breath and ventricular pauses.

In case of overdose, it is recommended to monitor for these adverse effects and perform ECG monitoring.

Treatment:

in case of overdose, symptomatic therapy should be carried out in accordance with local standards. Brilinta® is not excreted during hemodialysis (see “Special Instructions”), the antidote is unknown.

Due to platelet inhibition, an increase in the duration of bleeding is the expected pharmacological effect of overdose with Brilinta®, therefore, if bleeding develops, appropriate supportive measures should be taken.

special instructions

Risk of bleeding

In patients with acute coronary syndrome treated with Brilinta® and acetylsalicylic acid, there was an increased risk of non-CABG major bleeding and bleeding requiring increased medical attention, such as major + minor bleeding according to the PLATO

, but the risk of fatal/life-threatening bleeding did not increase (see "Side effects").

When prescribing Brilinta®, the balance between the benefit of preventing atherothrombotic events and the risk in patients with an increased risk of bleeding should be assessed.

If clinically indicated, Brilinta® should be used with caution in the following patient groups:

- patients are predisposed to the development of bleeding (for example, due to recent trauma, recent surgery, bleeding disorders, active or recent gastrointestinal bleeding). Use of

Features of the rehabilitation period and recovery after stenting

The duration of cardiac recovery after cardiac stent placement is influenced by many factors. The basic category includes strict adherence to medical recommendations:

• Do not stop therapy on your own without consulting your doctor. Treatment at the postoperative stage always involves the use of two antithrombotic drugs (the main one is Aspirin, the additional one is Brilinta or Clopidogrel, Prasugrel, Effient). Your doctor decides which one to take.
• Pay attention to adequate physical activity. Light walking becomes possible already 2-3 days after discharge (10-15 minutes once a day at first, and then, gradually increasing the duration of the walk by 5 minutes, switch to twice 30-minute walks).
• Rest and sleep properly. If you have problems falling asleep, it is important to tell your doctor so that he can prescribe sedatives or sleeping pills.
• Avoid taking hot baths and showers. Heat helps dilate blood vessels and reduce blood pressure.
• Refrain from driving a car for the first 3-4 months. And if a stent is installed due to an exacerbation of coronary syndrome, the threat of a heart attack or during one, working as a driver will become impossible (due to increased stress).
• Follow a diet. An important condition for recovery is that the diet consists of fortified foods, rich in minerals and dietary fiber. Why do the menu include greens, vegetables, whole grains, legumes, fish, low-fat dairy products, chicken, turkey. While fatty, salty foods and sugary drinks should be excluded.
• Stop smoking. Tobacco leads to narrowing of arteries and damage to the endothelium of blood vessels, which increases the risk of developing embolism.

Beginning sexual activity earlier than 3 weeks after surgery is dangerous, since sex is comparable to average physical activity (similar to climbing the 2nd floor). If pain in the heart and shortness of breath occur during intimacy, be sure to consult a cardiologist. If erectile dysfunction develops, you should not raise the question of how much Brilinta to drink - therapy must definitely continue, otherwise there is a high risk of life-threatening.